Identification

Name
Metyrosine
Accession Number
DB00765  (APRD01112)
Type
Small Molecule
Groups
Approved
Description

An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed)

Structure
Thumb
Synonyms
  • (-)-alpha-Methyl-L-tyrosine
  • (–)-α-methyl-L-tyrosine
  • (S)-alpha-Methyltyrosine
  • Methyltyrosine
  • Metirosin
  • Metirosina
  • Métirosine
  • Metirosine
  • Metirosinum
  • α-methyl-L-p-tyrosine
  • α-methyl-p-tyrosine
  • α-methyl-para-tyrosine
  • α-MPT
External IDs
357 O / L 588 / L 588357-0 / L-588357-0 / MK 781 / MK-781
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DemserCapsule250 mg/1OralAton Pharma, Inc.1979-10-03Not applicableUs
Categories
UNII
DOQ0J0TPF7
CAS number
672-87-7
Weight
Average: 195.2151
Monoisotopic: 195.089543287
Chemical Formula
C10H13NO3
InChI Key
NHTGHBARYWONDQ-JTQLQIEISA-N
InChI
InChI=1S/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/m0/s1
IUPAC Name
(2S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid
SMILES
C[[email protected]](N)(CC1=CC=C(O)C=C1)C(O)=O

Pharmacology

Indication

For use in the treatment of patients with pheochromocytoma, for preoperative preparation of patients for surgery, management of patients when surgery is contraindicated, and chronic treatment of patients with malignant pheochromocytoma.

Structured Indications
Pharmacodynamics

In patients with pheochromocytoma, who produce excessive amounts of norepinephrine and epinephrine, administration of one to four grams of metyrosine per day has reduced catecholamine biosynthesis from about 35 to 80 percent as measured by the total excretion of catecholamines and their metabolites (metanephrine and vanillylmandelic acid). The maximum biochemical effect usually occurs within two to three days, and the urinary concentration of catecholamines and their metabolites usually returns to pretreatment levels within three to four days after metyrosine is discontinued. Most patients with pheochromocytoma treated with metyrosine experience decreased frequency and severity of hypertensive attacks with their associated headache, nausea, sweating, and tachycardia. In patients who respond, blood pressure decreases progressively during the first two days of therapy with metyrosine; after withdrawal, blood pressure usually increases gradually to pretreatment values within two to three days.

Mechanism of action

Metyrosine inhibits tyrosine hydroxylase, which catalyzes the first transformation in catecholamine biosynthesis, i.e., the conversion of tyrosine to dihydroxyphenylalanine (DOPA). Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines and their synthesis. This consequently, depletes the levels of the catecholamines dopamine, adrenaline and noradrenaline in the body,usually measured as decreased urinary excretion of catecholamines and their metabolites. One main end result of the catecholamine depletion is a decrease in blood presure.

TargetActionsOrganism
ATyrosine 3-monooxygenase
binder
Human
Absorption

Well absorbed from the gastrointestinal tract.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Little biotransformation, with catechol metabolites accounting for less than 1% of the administered dose.

Route of elimination

Because the first step is also the rate-limiting step, blockade of tyrosine hydroxylase activity results in decreased endogenous levels of catecholamines, usually measured as decreased urinary excretion of catecholamines and their metabolites.

Half life

3.4 to 3.7 hours

Clearance
Not Available
Toxicity

Signs of metyrosine overdosage include those central nervous system effects observed in some patients even at low dosages. At doses exceeding 2000 mg/day, some degree of sedation or feeling of fatigue may persist. Doses of 2000-4000 mg/day can result in anxiety or agitated depression, neuromuscular effects (including fine tremor of the hands, gross tremor of the trunk, tightening of the jaw with trismus), diarrhea, and decreased salivation with dry mouth. The acute toxicity of metyrosine was 442 mg/kg and 752 mg/kg in the female mouse and rat respectively.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-Nitroindazole7-Nitroindazole may increase the sedative activities of Metyrosine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Metyrosine.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Metyrosine.Approved
AcepromazineAcepromazine may increase the sedative activities of Metyrosine.Approved, Vet Approved
AceprometazineAceprometazine may increase the sedative activities of Metyrosine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Acetophenazine.Approved
AdipiplonAdipiplon may increase the sedative activities of Metyrosine.Investigational
AgomelatineAgomelatine may increase the sedative activities of Metyrosine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Metyrosine is combined with Alaproclate.Experimental
AlfaxaloneAlfaxalone may increase the sedative activities of Metyrosine.Vet Approved
AlfentanilAlfentanil may increase the sedative activities of Metyrosine.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Metyrosine.Approved, Investigational
AliskirenAliskiren may increase the hypotensive activities of Metyrosine.Approved, Investigational
AllopregnanoloneAllopregnanolone may increase the sedative activities of Metyrosine.Investigational
AlphacetylmethadolAlphacetylmethadol may increase the sedative activities of Metyrosine.Experimental, Illicit
AlphaprodineAlphaprodine may increase the sedative activities of Metyrosine.Illicit
AlprazolamAlprazolam may increase the sedative activities of Metyrosine.Approved, Illicit, Investigational
AlprenololAlprenolol may increase the hypotensive activities of Metyrosine.Approved, Withdrawn
AmbrisentanMetyrosine may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineMetyrosine may increase the hypotensive activities of Amifostine.Approved, Investigational
AmineptineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Amineptine.Illicit, Withdrawn
AmisulprideAmisulpride may increase the sedative activities of Metyrosine.Approved, Investigational
AmitriptylineAmitriptyline may increase the sedative activities of Metyrosine.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Metyrosine.Approved
AmobarbitalAmobarbital may increase the sedative activities of Metyrosine.Approved, Illicit
AmoxapineAmoxapine may increase the sedative activities of Metyrosine.Approved
AmperozideAmperozide may increase the sedative activities of Metyrosine.Experimental
AmphetamineAmphetamine may increase the hypotensive activities of Metyrosine.Approved, Illicit
AripiprazoleAripiprazole may increase the sedative activities of Metyrosine.Approved, Investigational
ArticaineArticaine may increase the sedative activities of Metyrosine.Approved
AsenapineAsenapine may increase the sedative activities of Metyrosine.Approved
AtenololAtenolol may increase the hypotensive activities of Metyrosine.Approved
AvanafilAvanafil may increase the antihypertensive activities of Metyrosine.Approved
AzaperoneAzaperone may increase the sedative activities of Metyrosine.Investigational, Vet Approved
AzelastineAzelastine may increase the sedative activities of Metyrosine.Approved
BaclofenBaclofen may increase the sedative activities of Metyrosine.Approved
BarbitalBarbital may increase the sedative activities of Metyrosine.Illicit
BenazeprilBenazepril may increase the hypotensive activities of Metyrosine.Approved, Investigational
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Metyrosine.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Metyrosine.Withdrawn
BenperidolBenperidol may increase the sedative activities of Metyrosine.Investigational
BenzocaineBenzocaine may increase the sedative activities of Metyrosine.Approved
Benzyl alcoholBenzyl alcohol may increase the sedative activities of Metyrosine.Approved
BepridilBepridil may increase the hypotensive activities of Metyrosine.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Metyrosine.Approved
BethanidineBethanidine may increase the hypotensive activities of Metyrosine.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Metyrosine.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Metyrosine is combined with Bifeprunox.Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Metyrosine.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Metyrosine.Approved
BosentanBosentan may increase the hypotensive activities of Metyrosine.Approved, Investigational
BQ-123BQ-123 may increase the hypotensive activities of Metyrosine.Investigational
BretyliumBretylium may increase the hypotensive activities of Metyrosine.Approved
BrexpiprazoleBrexpiprazole may increase the sedative activities of Metyrosine.Approved
BrimonidineBrimonidine may increase the sedative activities of Metyrosine.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Metyrosine.Experimental
BromazepamBromazepam may increase the sedative activities of Metyrosine.Approved, Illicit
BromisovalBromisoval may increase the sedative activities of Metyrosine.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Metyrosine is combined with Bromperidol.Investigational
BrompheniramineBrompheniramine may increase the sedative activities of Metyrosine.Approved
BrotizolamBrotizolam may increase the sedative activities of Metyrosine.Approved, Investigational, Withdrawn
BupivacaineBupivacaine may increase the sedative activities of Metyrosine.Approved, Investigational
BupranololBupranolol may increase the hypotensive activities of Metyrosine.Approved
BuprenorphineBuprenorphine may increase the sedative activities of Metyrosine.Approved, Illicit, Investigational, Vet Approved
BuspironeBuspirone may increase the sedative activities of Metyrosine.Approved, Investigational
ButabarbitalButabarbital may increase the sedative activities of Metyrosine.Approved, Illicit
ButacaineButacaine may increase the sedative activities of Metyrosine.Vet Approved
ButalbitalButalbital may increase the sedative activities of Metyrosine.Approved, Illicit
ButambenButamben may increase the sedative activities of Metyrosine.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Butaperazine.Experimental
ButethalButethal may increase the sedative activities of Metyrosine.Approved, Illicit
ButorphanolButorphanol may increase the sedative activities of Metyrosine.Approved, Illicit, Vet Approved
CadralazineCadralazine may increase the hypotensive activities of Metyrosine.Experimental
CafedrineCafedrine may increase the hypotensive activities of Metyrosine.Investigational
CandesartanCandesartan may increase the hypotensive activities of Metyrosine.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Metyrosine.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Metyrosine.Experimental
CanertinibCanertinib may increase the sedative activities of Metyrosine.Investigational
CaptoprilCaptopril may increase the hypotensive activities of Metyrosine.Approved
CarbamazepineCarbamazepine may increase the sedative activities of Metyrosine.Approved, Investigational
CarbinoxamineCarbinoxamine may increase the sedative activities of Metyrosine.Approved
CarfentanilCarfentanil may increase the sedative activities of Metyrosine.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Cariprazine.Approved
CarisoprodolCarisoprodol may increase the sedative activities of Metyrosine.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Metyrosine.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Metyrosine.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Metyrosine.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Metyrosine.Approved, Investigational
CetirizineCetirizine may increase the sedative activities of Metyrosine.Approved
Chloral hydrateChloral hydrate may increase the sedative activities of Metyrosine.Approved, Illicit, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the sedative activities of Metyrosine.Approved, Illicit
ChlormezanoneChlormezanone may increase the sedative activities of Metyrosine.Approved, Investigational, Withdrawn
ChloroprocaineChloroprocaine may increase the sedative activities of Metyrosine.Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Metyrosine.Approved, Vet Approved
ChlorphenamineChlorphenamine may increase the sedative activities of Metyrosine.Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Chlorproethazine.Experimental
ChlorpromazineChlorpromazine may increase the sedative activities of Metyrosine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may increase the sedative activities of Metyrosine.Approved, Investigational, Withdrawn
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Metyrosine.Approved
ChlorzoxazoneChlorzoxazone may increase the sedative activities of Metyrosine.Approved
CicletanineCicletanine may increase the hypotensive activities of Metyrosine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Metyrosine.Approved
CinchocaineCinchocaine may increase the sedative activities of Metyrosine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Metyrosine is combined with Citalopram.Approved
ClemastineClemastine may increase the sedative activities of Metyrosine.Approved
ClidiniumClidinium may increase the sedative activities of Metyrosine.Approved
ClobazamClobazam may increase the sedative activities of Metyrosine.Approved, Illicit
clomethiazoleclomethiazole may increase the sedative activities of Metyrosine.Investigational
ClomipramineClomipramine may increase the sedative activities of Metyrosine.Approved, Vet Approved
ClonazepamClonazepam may increase the sedative activities of Metyrosine.Approved, Illicit
ClonidineClonidine may increase the sedative activities of Metyrosine.Approved
ClopenthixolClopenthixol may increase the sedative activities of Metyrosine.Experimental
CloranololCloranolol may increase the hypotensive activities of Metyrosine.Experimental
ClorazepateClorazepate may increase the sedative activities of Metyrosine.Approved, Illicit
ClothiapineClothiapine may increase the sedative activities of Metyrosine.Experimental
ClozapineClozapine may increase the sedative activities of Metyrosine.Approved
CocaineCocaine may increase the sedative activities of Metyrosine.Approved, Illicit
CodeineCodeine may increase the sedative activities of Metyrosine.Approved, Illicit
CryptenamineCryptenamine may increase the hypotensive activities of Metyrosine.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Cyamemazine.Approved
CyclizineCyclizine may increase the sedative activities of Metyrosine.Approved
CyclobenzaprineCyclobenzaprine may increase the sedative activities of Metyrosine.Approved
CyclopenthiazideCyclopenthiazide may increase the hypotensive activities of Metyrosine.Experimental
CyclothiazideCyclothiazide may increase the hypotensive activities of Metyrosine.Approved
CyproheptadineCyproheptadine may increase the sedative activities of Metyrosine.Approved
DantroleneDantrolene may increase the sedative activities of Metyrosine.Approved
DapiprazoleDapiprazole may increase the sedative activities of Metyrosine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Dapoxetine.Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Metyrosine.Approved, Investigational
DelaprilDelapril may increase the hypotensive activities of Metyrosine.Experimental
DeramciclaneDeramciclane may increase the sedative activities of Metyrosine.Investigational
DeserpidineMetyrosine may increase the hypotensive activities of Deserpidine.Approved
DesfluraneDesflurane may increase the sedative activities of Metyrosine.Approved
DesipramineDesipramine may increase the sedative activities of Metyrosine.Approved
DesloratadineDesloratadine may increase the sedative activities of Metyrosine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Desvenlafaxine.Approved
DetomidineDetomidine may increase the sedative activities of Metyrosine.Vet Approved
DexbrompheniramineDexbrompheniramine may increase the sedative activities of Metyrosine.Approved
DexmedetomidineDexmedetomidine may increase the sedative activities of Metyrosine.Approved, Vet Approved
DextromoramideDextromoramide may increase the sedative activities of Metyrosine.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the sedative activities of Metyrosine.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the sedative activities of Metyrosine.Approved, Investigational
DiazepamDiazepam may increase the sedative activities of Metyrosine.Approved, Illicit, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Metyrosine.Approved
DibenzepinThe risk or severity of adverse effects can be increased when Metyrosine is combined with Dibenzepin.Experimental
Diethyl etherDiethyl ether may increase the sedative activities of Metyrosine.Experimental
diethylnorsperminediethylnorspermine may increase the hypotensive activities of Metyrosine.Investigational
DifenoxinDifenoxin may increase the sedative activities of Metyrosine.Approved, Illicit
DihydralazineDihydralazine may increase the hypotensive activities of Metyrosine.Investigational
DihydrocodeineDihydrocodeine may increase the sedative activities of Metyrosine.Approved, Illicit
DihydroetorphineDihydroetorphine may increase the sedative activities of Metyrosine.Experimental, Illicit
DihydromorphineDihydromorphine may increase the sedative activities of Metyrosine.Experimental, Illicit
DiltiazemDiltiazem may increase the hypotensive activities of Metyrosine.Approved
DimenhydrinateDimenhydrinate may increase the sedative activities of Metyrosine.Approved
DiphenhydramineDiphenhydramine may increase the sedative activities of Metyrosine.Approved
DiphenoxylateDiphenoxylate may increase the sedative activities of Metyrosine.Approved, Illicit
DixyrazineDixyrazine may increase the sedative activities of Metyrosine.Experimental
DoramectinDoramectin may increase the sedative activities of Metyrosine.Vet Approved
DorzolamideDorzolamide may increase the hypotensive activities of Metyrosine.Approved
DosulepinThe risk or severity of adverse effects can be increased when Metyrosine is combined with Dosulepin.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Metyrosine.Approved
DoxepinDoxepin may increase the sedative activities of Metyrosine.Approved
DoxylamineDoxylamine may increase the sedative activities of Metyrosine.Approved, Vet Approved
DPDPEDPDPE may increase the sedative activities of Metyrosine.Experimental
DroperidolThe risk or severity of adverse effects can be increased when Metyrosine is combined with Droperidol.Approved, Vet Approved
DrotebanolDrotebanol may increase the sedative activities of Metyrosine.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Duloxetine.Approved
DyclonineDyclonine may increase the sedative activities of Metyrosine.Approved
EcgonineEcgonine may increase the sedative activities of Metyrosine.Experimental, Illicit
EcopipamEcopipam may increase the sedative activities of Metyrosine.Investigational
EfavirenzEfavirenz may increase the sedative activities of Metyrosine.Approved, Investigational
EfonidipineEfonidipine may increase the hypotensive activities of Metyrosine.Approved, Investigational
EltanoloneEltanolone may increase the sedative activities of Metyrosine.Investigational
EnalaprilEnalapril may increase the hypotensive activities of Metyrosine.Approved, Vet Approved
EnalaprilatEnalaprilat may increase the hypotensive activities of Metyrosine.Approved
EndralazineEndralazine may increase the hypotensive activities of Metyrosine.Experimental
EnfluraneEnflurane may increase the sedative activities of Metyrosine.Approved, Investigational, Vet Approved
EntacaponeEntacapone may increase the sedative activities of Metyrosine.Approved, Investigational
EpanololEpanolol may increase the hypotensive activities of Metyrosine.Experimental
EpoprostenolEpoprostenol may increase the hypotensive activities of Metyrosine.Approved
EprosartanEprosartan may increase the hypotensive activities of Metyrosine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Metyrosine is combined with Escitalopram.Approved, Investigational
EsmirtazapineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Esmirtazapine.Investigational
EstazolamEstazolam may increase the sedative activities of Metyrosine.Approved, Illicit
EszopicloneEszopiclone may increase the sedative activities of Metyrosine.Approved
EthanolEthanol may increase the sedative activities of Metyrosine.Approved
EthchlorvynolEthchlorvynol may increase the sedative activities of Metyrosine.Approved, Illicit, Withdrawn
EthosuximideEthosuximide may increase the sedative activities of Metyrosine.Approved
EthotoinEthotoin may increase the sedative activities of Metyrosine.Approved
Ethyl carbamateEthyl carbamate may increase the sedative activities of Metyrosine.Withdrawn
Ethyl chlorideEthyl chloride may increase the sedative activities of Metyrosine.Experimental, Investigational
Ethyl loflazepateEthyl loflazepate may increase the sedative activities of Metyrosine.Approved, Illicit
EthylmorphineEthylmorphine may increase the sedative activities of Metyrosine.Approved, Illicit
EtidocaineEtidocaine may increase the sedative activities of Metyrosine.Approved
EtifoxineEtifoxine may increase the sedative activities of Metyrosine.Investigational, Withdrawn
EtizolamEtizolam may increase the sedative activities of Metyrosine.Approved
EtomidateEtomidate may increase the sedative activities of Metyrosine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Metyrosine is combined with Etoperidone.Withdrawn
EtorphineEtorphine may increase the sedative activities of Metyrosine.Illicit, Vet Approved
EzogabineEzogabine may increase the sedative activities of Metyrosine.Approved
FelbamateFelbamate may increase the sedative activities of Metyrosine.Approved
FelodipineFelodipine may increase the hypotensive activities of Metyrosine.Approved, Investigational
FencamfamineFencamfamine may increase the sedative activities of Metyrosine.Approved, Illicit, Withdrawn
FenoldopamFenoldopam may increase the hypotensive activities of Metyrosine.Approved
FentanylFentanyl may increase the sedative activities of Metyrosine.Approved, Illicit, Investigational, Vet Approved
Ferulic acidFerulic acid may increase the hypotensive activities of Metyrosine.Experimental
FexofenadineFexofenadine may increase the sedative activities of Metyrosine.Approved
FlibanserinFlibanserin may increase the sedative activities of Metyrosine.Approved
FluanisoneFluanisone may increase the sedative activities of Metyrosine.Experimental
FludiazepamFludiazepam may increase the sedative activities of Metyrosine.Approved, Illicit
FlunarizineFlunarizine may increase the sedative activities of Metyrosine.Approved
FlunitrazepamFlunitrazepam may increase the sedative activities of Metyrosine.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the sedative activities of Metyrosine.Approved, Withdrawn
FluphenazineFluphenazine may increase the sedative activities of Metyrosine.Approved
FlurazepamFlurazepam may increase the sedative activities of Metyrosine.Approved, Illicit
FluspirileneFluspirilene may increase the sedative activities of Metyrosine.Approved, Investigational
Fluticasone propionateFluticasone propionate may increase the sedative activities of Metyrosine.Approved
FluvoxamineFluvoxamine may increase the sedative activities of Metyrosine.Approved, Investigational
FosinoprilFosinopril may increase the hypotensive activities of Metyrosine.Approved
FosphenytoinFosphenytoin may increase the sedative activities of Metyrosine.Approved
FospropofolFospropofol may increase the sedative activities of Metyrosine.Approved, Illicit, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Metyrosine.Approved, Investigational, Vet Approved
GabapentinGabapentin may increase the sedative activities of Metyrosine.Approved, Investigational
Gabapentin EnacarbilGabapentin Enacarbil may increase the sedative activities of Metyrosine.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the sedative activities of Metyrosine.Approved, Illicit, Investigational
GepironeGepirone may increase the sedative activities of Metyrosine.Investigational
GlutethimideGlutethimide may increase the sedative activities of Metyrosine.Approved, Illicit
GuanabenzGuanabenz may increase the hypotensive activities of Metyrosine.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Metyrosine.Approved
GuanazodineMetyrosine may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Metyrosine.Approved
GuanfacineGuanfacine may increase the sedative activities of Metyrosine.Approved, Investigational
GuanoclorMetyrosine may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzMetyrosine may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanMetyrosine may increase the hypotensive activities of Guanoxan.Experimental
HalazepamHalazepam may increase the sedative activities of Metyrosine.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the sedative activities of Metyrosine.Approved
HalothaneHalothane may increase the sedative activities of Metyrosine.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Metyrosine.Experimental
HeroinHeroin may increase the sedative activities of Metyrosine.Approved, Illicit, Investigational
HexamethoniumHexamethonium may increase the hypotensive activities of Metyrosine.Experimental
HexobarbitalHexobarbital may increase the sedative activities of Metyrosine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Metyrosine.Experimental
HydralazineHydralazine may increase the hypotensive activities of Metyrosine.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Metyrosine.Approved, Vet Approved
HydrocodoneHydrocodone may increase the sedative activities of Metyrosine.Approved, Illicit
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Metyrosine.Approved, Investigational
HydromorphoneHydromorphone may increase the sedative activities of Metyrosine.Approved, Illicit
HydroxyzineHydroxyzine may increase the sedative activities of Metyrosine.Approved
IloperidoneIloperidone may increase the sedative activities of Metyrosine.Approved
IloprostIloprost may increase the hypotensive activities of Metyrosine.Approved, Investigational
ImidaprilImidapril may increase the hypotensive activities of Metyrosine.Investigational
ImipramineImipramine may increase the sedative activities of Metyrosine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the hypotensive activities of Metyrosine.Approved
IndenololIndenolol may increase the hypotensive activities of Metyrosine.Withdrawn
IndiplonIndiplon may increase the sedative activities of Metyrosine.Investigational
IndoraminIndoramin may increase the hypotensive activities of Metyrosine.Withdrawn
IprindoleThe risk or severity of adverse effects can be increased when Metyrosine is combined with Iprindole.Experimental
IproclozideIproclozide may increase the hypotensive activities of Metyrosine.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Metyrosine.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Metyrosine.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Metyrosine.Approved
IsofluraneIsoflurane may increase the sedative activities of Metyrosine.Approved, Vet Approved
IsradipineIsradipine may increase the hypotensive activities of Metyrosine.Approved
KetamineKetamine may increase the sedative activities of Metyrosine.Approved, Vet Approved
KetanserinKetanserin may increase the hypotensive activities of Metyrosine.Investigational
KetazolamKetazolam may increase the sedative activities of Metyrosine.Approved
KetobemidoneKetobemidone may increase the sedative activities of Metyrosine.Approved, Investigational
LabetalolLabetalol may increase the hypotensive activities of Metyrosine.Approved
LacidipineLacidipine may increase the hypotensive activities of Metyrosine.Approved, Investigational
LamotrigineLamotrigine may increase the sedative activities of Metyrosine.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Metyrosine.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Metyrosine.Approved, Investigational
LevetiracetamLevetiracetam may increase the sedative activities of Metyrosine.Approved, Investigational
LevobupivacaineLevobupivacaine may increase the sedative activities of Metyrosine.Approved, Investigational
LevocabastineLevocabastine may increase the sedative activities of Metyrosine.Approved
LevocetirizineLevocetirizine may increase the sedative activities of Metyrosine.Approved
LevodopaLevodopa may increase the sedative activities of Metyrosine.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the sedative activities of Metyrosine.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Metyrosine is combined with Levomilnacipran.Approved
LevorphanolLevorphanol may increase the sedative activities of Metyrosine.Approved
LidocaineLidocaine may increase the sedative activities of Metyrosine.Approved, Vet Approved
LinsidomineLinsidomine may increase the hypotensive activities of Metyrosine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Metyrosine.Approved, Investigational
LithiumLithium may increase the sedative activities of Metyrosine.Approved
LofentanilLofentanil may increase the sedative activities of Metyrosine.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Lofepramine.Experimental
LofexidineLofexidine may increase the hypotensive activities of Metyrosine.Approved, Investigational
LoprazolamLoprazolam may increase the sedative activities of Metyrosine.Experimental
LoratadineLoratadine may increase the sedative activities of Metyrosine.Approved
LorazepamLorazepam may increase the sedative activities of Metyrosine.Approved
LormetazepamLormetazepam may increase the sedative activities of Metyrosine.Approved
LosartanLosartan may increase the hypotensive activities of Metyrosine.Approved
LoxapineLoxapine may increase the sedative activities of Metyrosine.Approved
LurasidoneLurasidone may increase the sedative activities of Metyrosine.Approved
MacitentanMetyrosine may increase the hypotensive activities of Macitentan.Approved
Magnesium SulfateMagnesium Sulfate may increase the sedative activities of Metyrosine.Approved, Vet Approved
ManidipineManidipine may increase the hypotensive activities of Metyrosine.Approved, Investigational
MaprotilineMaprotiline may increase the sedative activities of Metyrosine.Approved
MebanazineMebanazine may increase the hypotensive activities of Metyrosine.Withdrawn
MebicarMebicar may increase the sedative activities of Metyrosine.Experimental
MecamylamineMecamylamine may increase the hypotensive activities of Metyrosine.Approved
MeclizineMeclizine may increase the sedative activities of Metyrosine.Approved
MedazepamMedazepam may increase the sedative activities of Metyrosine.Experimental
MedetomidineMedetomidine may increase the sedative activities of Metyrosine.Vet Approved
MelatoninMelatonin may increase the sedative activities of Metyrosine.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the sedative activities of Metyrosine.Approved, Investigational
MepivacaineMepivacaine may increase the sedative activities of Metyrosine.Approved, Vet Approved
MeprobamateMeprobamate may increase the sedative activities of Metyrosine.Approved, Illicit
MeptazinolMeptazinol may increase the sedative activities of Metyrosine.Experimental
MesoridazineMesoridazine may increase the sedative activities of Metyrosine.Approved, Investigational
MetaxaloneMetaxalone may increase the sedative activities of Metyrosine.Approved
MethadoneMethadone may increase the sedative activities of Metyrosine.Approved
Methadyl AcetateMethadyl Acetate may increase the sedative activities of Metyrosine.Approved, Illicit
MethapyrileneMethapyrilene may increase the sedative activities of Metyrosine.Withdrawn
MethaqualoneMethaqualone may increase the sedative activities of Metyrosine.Illicit, Withdrawn
MethocarbamolMethocarbamol may increase the sedative activities of Metyrosine.Approved, Vet Approved
MethohexitalMethohexital may increase the sedative activities of Metyrosine.Approved
MethoserpidineMetyrosine may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineMethotrimeprazine may increase the sedative activities of Metyrosine.Approved
MethoxyfluraneMethoxyflurane may increase the sedative activities of Metyrosine.Approved, Investigational, Vet Approved
MethsuximideMethsuximide may increase the sedative activities of Metyrosine.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Metyrosine.Approved
MethylecgonineMethylecgonine may increase the sedative activities of Metyrosine.Experimental
Methylene blueMethylene blue may increase the hypotensive activities of Metyrosine.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Metyrosine.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the sedative activities of Metyrosine.Approved
MetipranololMetipranolol may increase the hypotensive activities of Metyrosine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metyrosine is combined with Metoclopramide.Approved, Investigational
MetolazoneMetolazone may increase the hypotensive activities of Metyrosine.Approved
MetoprololMetoprolol may increase the hypotensive activities of Metyrosine.Approved, Investigational
MibefradilMibefradil may increase the hypotensive activities of Metyrosine.Investigational, Withdrawn
MidazolamMidazolam may increase the sedative activities of Metyrosine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Metyrosine is combined with Milnacipran.Approved
MinaprineMinaprine may increase the hypotensive activities of Metyrosine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Metyrosine.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Metyrosine.Investigational
MirtazapineMirtazapine may increase the sedative activities of Metyrosine.Approved
MoclobemideMoclobemide may increase the hypotensive activities of Metyrosine.Approved
MoexiprilMoexipril may increase the hypotensive activities of Metyrosine.Approved
MolindoneMolindone may increase the sedative activities of Metyrosine.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Metyrosine.Approved, Investigational
MoperoneThe risk or severity of adverse effects can be increased when Metyrosine is combined with Moperone.Experimental
MorphineMorphine may increase the sedative activities of Metyrosine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Mosapramine.Experimental
MoxonidineMoxonidine may increase the hypotensive activities of Metyrosine.Approved, Investigational
MuzolimineMuzolimine may increase the hypotensive activities of Metyrosine.Experimental
NabiloneNabilone may increase the sedative activities of Metyrosine.Approved, Investigational
NadololNadolol may increase the hypotensive activities of Metyrosine.Approved
NaftopidilNaftopidil may increase the hypotensive activities of Metyrosine.Investigational
NalbuphineNalbuphine may increase the sedative activities of Metyrosine.Approved
NebivololNebivolol may increase the hypotensive activities of Metyrosine.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Metyrosine is combined with Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the hypotensive activities of Metyrosine.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Metyrosine.Approved
NicorandilNicorandil may increase the hypotensive activities of Metyrosine.Approved, Investigational
NiguldipineNiguldipine may increase the hypotensive activities of Metyrosine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Metyrosine.Approved, Investigational
NimodipineNimodipine may increase the hypotensive activities of Metyrosine.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Metyrosine.Approved
NitrazepamNitrazepam may increase the sedative activities of Metyrosine.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Metyrosine.Approved, Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Metyrosine.Approved
Nitrous oxideNitrous oxide may increase the sedative activities of Metyrosine.Approved, Vet Approved
NorfluraneNorflurane may increase the sedative activities of Metyrosine.Investigational
NormethadoneNormethadone may increase the sedative activities of Metyrosine.Approved, Illicit
NortriptylineNortriptyline may increase the sedative activities of Metyrosine.Approved
ObinutuzumabMetyrosine may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Metyrosine.Withdrawn
OlanzapineOlanzapine may increase the sedative activities of Metyrosine.Approved, Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Metyrosine.Approved, Investigational
OlopatadineOlopatadine may increase the sedative activities of Metyrosine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Metyrosine.Investigational
OndansetronOndansetron may increase the sedative activities of Metyrosine.Approved
OpipramolThe risk or severity of adverse effects can be increased when Metyrosine is combined with Opipramol.Investigational
OpiumOpium may increase the sedative activities of Metyrosine.Approved, Illicit
OrphenadrineOrphenadrine may increase the sedative activities of Metyrosine.Approved
OsanetantOsanetant may increase the sedative activities of Metyrosine.Investigational
OxazepamOxazepam may increase the sedative activities of Metyrosine.Approved
OxethazaineOxethazaine may increase the sedative activities of Metyrosine.Approved, Investigational
OxprenololOxprenolol may increase the sedative activities of Metyrosine.Approved
OxybuprocaineOxybuprocaine may increase the sedative activities of Metyrosine.Approved
OxycodoneOxycodone may increase the sedative activities of Metyrosine.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the sedative activities of Metyrosine.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Oxypertine.Experimental
PaliperidonePaliperidone may increase the sedative activities of Metyrosine.Approved
ParaldehydeParaldehyde may increase the sedative activities of Metyrosine.Approved, Investigational
PargylinePargyline may increase the hypotensive activities of Metyrosine.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Paroxetine.Approved, Investigational
PenbutololPenbutolol may increase the hypotensive activities of Metyrosine.Approved, Investigational
PenfluridolPenfluridol may increase the sedative activities of Metyrosine.Experimental
PentazocinePentazocine may increase the sedative activities of Metyrosine.Approved, Vet Approved
PentobarbitalPentobarbital may increase the sedative activities of Metyrosine.Approved, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Metyrosine.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Metyrosine.Approved, Investigational
PerampanelPerampanel may increase the sedative activities of Metyrosine.Approved
PerazinePerazine may increase the sedative activities of Metyrosine.Investigational
PerindoprilPerindopril may increase the hypotensive activities of Metyrosine.Approved
PerospironePerospirone may increase the sedative activities of Metyrosine.Approved
PerphenazinePerphenazine may increase the sedative activities of Metyrosine.Approved
PethidinePethidine may increase the sedative activities of Metyrosine.Approved
PhenazocinePhenazocine may increase the sedative activities of Metyrosine.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Metyrosine.Approved
PhenibutPhenibut may increase the sedative activities of Metyrosine.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Metyrosine.Withdrawn
PhenobarbitalPhenobarbital may increase the sedative activities of Metyrosine.Approved
PhenoperidinePhenoperidine may increase the sedative activities of Metyrosine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Metyrosine.Approved
PhenoxyethanolPhenoxyethanol may increase the sedative activities of Metyrosine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Metyrosine.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Metyrosine.Approved
PhenytoinPhenytoin may increase the sedative activities of Metyrosine.Approved, Vet Approved
PimozidePimozide may increase the sedative activities of Metyrosine.Approved
PinacidilPinacidil may increase the hypotensive activities of Metyrosine.Withdrawn
PindololPindolol may increase the hypotensive activities of Metyrosine.Approved
PipamperonePipamperone may increase the sedative activities of Metyrosine.Approved, Investigational
PipotiazinePipotiazine may increase the sedative activities of Metyrosine.Approved, Investigational
PiritramidePiritramide may increase the sedative activities of Metyrosine.Investigational
PirlindolePirlindole may increase the hypotensive activities of Metyrosine.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Metyrosine.Withdrawn
PizotifenPizotifen may increase the sedative activities of Metyrosine.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Metyrosine.Experimental
PolythiazidePolythiazide may increase the hypotensive activities of Metyrosine.Approved
PomalidomidePomalidomide may increase the sedative activities of Metyrosine.Approved
PramocainePramocaine may increase the sedative activities of Metyrosine.Approved
PrazepamPrazepam may increase the sedative activities of Metyrosine.Approved, Illicit
PrazosinPrazosin may increase the hypotensive activities of Metyrosine.Approved
PregabalinPregabalin may increase the sedative activities of Metyrosine.Approved, Illicit, Investigational
PrilocainePrilocaine may increase the sedative activities of Metyrosine.Approved
PrimidonePrimidone may increase the sedative activities of Metyrosine.Approved, Vet Approved
ProcaineProcaine may increase the sedative activities of Metyrosine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Metyrosine.Approved
ProchlorperazineProchlorperazine may increase the sedative activities of Metyrosine.Approved, Vet Approved
PromazinePromazine may increase the sedative activities of Metyrosine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Promethazine.Approved
PropanididPropanidid may increase the sedative activities of Metyrosine.Experimental
ProparacaineProparacaine may increase the sedative activities of Metyrosine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Propericiazine.Approved
PropofolPropofol may increase the sedative activities of Metyrosine.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the sedative activities of Metyrosine.Approved
PropranololPropranolol may increase the hypotensive activities of Metyrosine.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Metyrosine is combined with Prothipendyl.Investigational
ProtriptylineProtriptyline may increase the sedative activities of Metyrosine.Approved
ProxibarbalProxibarbal may increase the sedative activities of Metyrosine.Experimental
PSD502PSD502 may increase the sedative activities of Metyrosine.Investigational
QuazepamQuazepam may increase the sedative activities of Metyrosine.Approved, Illicit
QuetiapineQuetiapine may increase the sedative activities of Metyrosine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Metyrosine.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Metyrosine.Approved
QuinisocaineQuinisocaine may increase the sedative activities of Metyrosine.Experimental
RacloprideRaclopride may increase the sedative activities of Metyrosine.Investigational
RamelteonRamelteon may increase the sedative activities of Metyrosine.Approved, Investigational
RamiprilRamipril may increase the hypotensive activities of Metyrosine.Approved
RasagilineRasagiline may increase the hypotensive activities of Metyrosine.Approved
RemifentanilRemifentanil may increase the sedative activities of Metyrosine.Approved
RemikirenRemikiren may increase the hypotensive activities of Metyrosine.Approved
RemoxiprideRemoxipride may increase the sedative activities of Metyrosine.Approved, Withdrawn
RescinnamineMetyrosine may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the sedative activities of Metyrosine.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Metyrosine.Investigational
RiociguatMetyrosine may increase the hypotensive activities of Riociguat.Approved
RisperidoneRisperidone may increase the sedative activities of Metyrosine.Approved, Investigational
RitanserinRitanserin may increase the sedative activities of Metyrosine.Investigational
RituximabMetyrosine may increase the hypotensive activities of Rituximab.Approved
RomifidineRomifidine may increase the sedative activities of Metyrosine.Vet Approved
RopivacaineRopivacaine may increase the sedative activities of Metyrosine.Approved
SafrazineSafrazine may increase the hypotensive activities of Metyrosine.Withdrawn
SaprisartanSaprisartan may increase the hypotensive activities of Metyrosine.Experimental
ScopolamineScopolamine may increase the sedative activities of Metyrosine.Approved
SecobarbitalSecobarbital may increase the sedative activities of Metyrosine.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Metyrosine.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the hypotensive activities of Metyrosine.Approved
SepranoloneSepranolone may increase the sedative activities of Metyrosine.Investigational
SertindoleSertindole may increase the sedative activities of Metyrosine.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the sedative activities of Metyrosine.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Metyrosine.Approved, Investigational
SitaxentanMetyrosine may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium oxybateSodium oxybate may increase the sedative activities of Metyrosine.Approved
SpiraprilSpirapril may increase the hypotensive activities of Metyrosine.Approved
StiripentolStiripentol may increase the sedative activities of Metyrosine.Approved
SufentanilSufentanil may increase the sedative activities of Metyrosine.Approved, Investigational
SulpirideSulpiride may increase the sedative activities of Metyrosine.Approved, Investigational
SultoprideSultopride may increase the sedative activities of Metyrosine.Experimental
SuvorexantSuvorexant may increase the sedative activities of Metyrosine.Approved
TadalafilTadalafil may increase the antihypertensive activities of Metyrosine.Approved, Investigational
TalinololTalinolol may increase the hypotensive activities of Metyrosine.Investigational
TandospironeTandospirone may increase the sedative activities of Metyrosine.Investigational
TapentadolTapentadol may increase the sedative activities of Metyrosine.Approved
TasimelteonTasimelteon may increase the sedative activities of Metyrosine.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Metyrosine.Approved, Investigational
TemazepamTemazepam may increase the sedative activities of Metyrosine.Approved
TemocaprilTemocapril may increase the hypotensive activities of Metyrosine.Experimental, Investigational
TerlipressinTerlipressin may increase the hypotensive activities of Metyrosine.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Tetrabenazine.Approved
TetracaineTetracaine may increase the sedative activities of Metyrosine.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the sedative activities of Metyrosine.Investigational
TetrodotoxinTetrodotoxin may increase the sedative activities of Metyrosine.Investigational
ThalidomideThalidomide may increase the sedative activities of Metyrosine.Approved, Investigational, Withdrawn
TheodrenalineTheodrenaline may increase the hypotensive activities of Metyrosine.Investigational
ThiamylalThiamylal may increase the sedative activities of Metyrosine.Approved, Vet Approved
ThiopentalThiopental may increase the sedative activities of Metyrosine.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Metyrosine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Thioproperazine.Approved
ThioridazineThioridazine may increase the sedative activities of Metyrosine.Approved, Withdrawn
ThiothixeneThiothixene may increase the sedative activities of Metyrosine.Approved
TiagabineTiagabine may increase the sedative activities of Metyrosine.Approved
TianeptineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Tianeptine.Approved, Investigational
TiaprideTiapride may increase the sedative activities of Metyrosine.Approved, Investigational
TiboloneTibolone may increase the hypotensive activities of Metyrosine.Approved, Investigational
TicrynafenTicrynafen may increase the hypotensive activities of Metyrosine.Withdrawn
TiletamineTiletamine may increase the sedative activities of Metyrosine.Vet Approved
TilidineTilidine may increase the sedative activities of Metyrosine.Experimental
TimololTimolol may increase the hypotensive activities of Metyrosine.Approved
TizanidineTizanidine may increase the sedative activities of Metyrosine.Approved
TolazolineTolazoline may increase the hypotensive activities of Metyrosine.Approved, Vet Approved
TolcaponeTolcapone may increase the sedative activities of Metyrosine.Approved, Withdrawn
TolonidineMetyrosine may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Metyrosine.Approved
TopiramateTopiramate may increase the sedative activities of Metyrosine.Approved
TorasemideTorasemide may increase the hypotensive activities of Metyrosine.Approved
TramadolTramadol may increase the sedative activities of Metyrosine.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Metyrosine.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the sedative activities of Metyrosine.Experimental
TranylcypromineTranylcypromine may increase the sedative activities of Metyrosine.Approved
TravoprostTravoprost may increase the hypotensive activities of Metyrosine.Approved
TrazodoneTrazodone may increase the sedative activities of Metyrosine.Approved, Investigational
TreprostinilTreprostinil may increase the hypotensive activities of Metyrosine.Approved, Investigational
TriazolamTriazolam may increase the sedative activities of Metyrosine.Approved
Tricaine methanesulfonateTricaine methanesulfonate may increase the sedative activities of Metyrosine.Vet Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Metyrosine.Approved, Vet Approved
TrichloroethyleneTrichloroethylene may increase the sedative activities of Metyrosine.Approved
TrifluoperazineTrifluoperazine may increase the sedative activities of Metyrosine.Approved
TrifluperidolTrifluperidol may increase the sedative activities of Metyrosine.Experimental
TriflupromazineTriflupromazine may increase the sedative activities of Metyrosine.Approved, Vet Approved
TrimazosinTrimazosin may increase the hypotensive activities of Metyrosine.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Metyrosine.Approved, Investigational
TrimipramineTrimipramine may increase the sedative activities of Metyrosine.Approved
TriprolidineTriprolidine may increase the sedative activities of Metyrosine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Metyrosine.Approved, Investigational
UnoprostoneUnoprostone may increase the hypotensive activities of Metyrosine.Approved
UrapidilUrapidil may increase the hypotensive activities of Metyrosine.Investigational
Valproic AcidValproic Acid may increase the sedative activities of Metyrosine.Approved, Investigational
ValsartanValsartan may increase the hypotensive activities of Metyrosine.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Metyrosine.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Venlafaxine.Approved
VeraliprideVeralipride may increase the sedative activities of Metyrosine.Experimental
VigabatrinVigabatrin may increase the sedative activities of Metyrosine.Approved
VincamineVincamine may increase the hypotensive activities of Metyrosine.Experimental
VinpocetineVinpocetine may increase the hypotensive activities of Metyrosine.Investigational
Vinyl etherVinyl ether may increase the sedative activities of Metyrosine.Experimental
VortioxetineVortioxetine may increase the sedative activities of Metyrosine.Approved
XenonXenon may increase the sedative activities of Metyrosine.Experimental
XipamideXipamide may increase the hypotensive activities of Metyrosine.Experimental
XylazineXylazine may increase the sedative activities of Metyrosine.Vet Approved
XylometazolineXylometazoline may increase the hypotensive activities of Metyrosine.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Metyrosine.Approved, Vet Approved
ZaleplonZaleplon may increase the sedative activities of Metyrosine.Approved, Illicit, Investigational
ZiconotideZiconotide may increase the sedative activities of Metyrosine.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the sedative activities of Metyrosine.Approved
ZofenoprilZofenopril may increase the hypotensive activities of Metyrosine.Experimental
ZolazepamZolazepam may increase the sedative activities of Metyrosine.Vet Approved
ZolpidemZolpidem may increase the sedative activities of Metyrosine.Approved
ZonisamideZonisamide may increase the sedative activities of Metyrosine.Approved, Investigational
ZopicloneZopiclone may increase the sedative activities of Metyrosine.Approved
ZotepineZotepine may increase the sedative activities of Metyrosine.Approved, Investigational
ZuclopenthixolZuclopenthixol may increase the sedative activities of Metyrosine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
US2868818
General References
Not Available
External Links
Human Metabolome Database
HMDB14903
KEGG Drug
D00762
KEGG Compound
C07921
PubChem Compound
441350
PubChem Substance
46506079
ChemSpider
390103
ChEBI
6912
ChEMBL
CHEMBL1200862
Therapeutic Targets Database
DAP000471
PharmGKB
PA450487
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
ATC Codes
C02KB01 — Metirosine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentPsychosis / Velo-Cardio-Facial Syndrome1
3Enrolling by InvitationTreatmentAutonomic Nervous System Diseases / Dopamine Beta-Hydroxylase Deficiency / Idiopathic orthostatic hypotension / Orthostatic Intolerance1
Not AvailableSuspendedDiagnosticBulimia Nervosa (BN) / Catechol-O-methyltransferase / Dopamine / Eating Disorders / Reward1

Pharmacoeconomics

Manufacturers
  • Aton pharma inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral250 mg/1
Prices
Unit descriptionCostUnit
Demser 250 mg capsule19.35USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)312.5 °CPhysProp
water solubilityVery slightly solubleNot Available
logP-1.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.48 mg/mLALOGPS
logP-1.9ALOGPS
logP-1.1ChemAxon
logS-1.9ALOGPS
pKa (Strongest Acidic)2.06ChemAxon
pKa (Strongest Basic)9.93ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area83.55 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity51.81 m3·mol-1ChemAxon
Polarizability19.9 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9918
Blood Brain Barrier-0.8678
Caco-2 permeable-0.7026
P-glycoprotein substrateSubstrate0.5286
P-glycoprotein inhibitor INon-inhibitor0.9891
P-glycoprotein inhibitor IINon-inhibitor0.9926
Renal organic cation transporterNon-inhibitor0.9278
CYP450 2C9 substrateNon-substrate0.8025
CYP450 2D6 substrateNon-substrate0.7432
CYP450 3A4 substrateNon-substrate0.6887
CYP450 1A2 substrateNon-inhibitor0.9459
CYP450 2C9 inhibitorNon-inhibitor0.951
CYP450 2D6 inhibitorNon-inhibitor0.9574
CYP450 2C19 inhibitorNon-inhibitor0.9116
CYP450 3A4 inhibitorNon-inhibitor0.892
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9735
Ames testNon AMES toxic0.9695
CarcinogenicityNon-carcinogens0.8681
BiodegradationNot ready biodegradable0.7891
Rat acute toxicity2.1516 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9852
hERG inhibition (predictor II)Non-inhibitor0.9728
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanoic acids. These are compounds with a structure containing a benzene ring conjugated to a propanoic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Phenylpropanoic acids
Sub Class
Not Available
Direct Parent
Phenylpropanoic acids
Alternative Parents
D-alpha-amino acids / Amphetamines and derivatives / Phenylpropanes / Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides
show 3 more
Substituents
3-phenylpropanoic-acid / Alpha-amino acid / Alpha-amino acid or derivatives / Amphetamine or derivatives / D-alpha-amino acid / Phenylpropane / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Phenol / Monocyclic benzene moiety
show 18 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
non-proteinogenic L-alpha-amino acid, L-tyrosine derivative (CHEBI:6912)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Binder
General Function
Tyrosine 3-monooxygenase activity
Specific Function
Plays an important role in the physiology of adrenergic neurons.
Gene Name
TH
Uniprot ID
P07101
Uniprot Name
Tyrosine 3-monooxygenase
Molecular Weight
58599.545 Da
References
  1. Nasrallah HA, Donnelly EF, Bigelow LB, Rivera-Calimlim L, Rogol A, Potkin S, Rauscher FP, Wyatt RJ: Inhibition of dopamine synthesis in chronic schizophrenia. Clinical ineffectiveness of metyrosine. Arch Gen Psychiatry. 1977 Jun;34(6):649-55. [PubMed:17374]
  2. Yoshimoto Y, Nakaso K, Nakashima K: L-dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells. FEBS Lett. 2005 Feb 14;579(5):1197-202. Epub 2005 Jan 21. [PubMed:15710413]
  3. Shore PA, Dorris RL: On a prime role for newly synthesized dopamine in striatal function. Eur J Pharmacol. 1975 Feb;30(2):315-8. [PubMed:1168577]
  4. Moore KE, Demarest KT, Johnston CA: Influence of prolactin on dopaminergic neuronal systems in the hypothalamus. Fed Proc. 1980 Sep;39(11):2912-6. [PubMed:7409209]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:42